Cargando…
Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680674/ https://www.ncbi.nlm.nih.gov/pubmed/36425305 http://dx.doi.org/10.2147/DDDT.S398024 |
| _version_ | 1784834465307033600 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9680674 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96806742022-11-23 Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] Drug Des Devel Ther Retraction Dove 2022-11-18 /pmc/articles/PMC9680674/ /pubmed/36425305 http://dx.doi.org/10.2147/DDDT.S398024 Text en © 2022 Dove Medical Press. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Retraction Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title | Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title_full | Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title_fullStr | Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title_full_unstemmed | Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title_short | Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction] |
| title_sort | development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation [retraction] |
| topic | Retraction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680674/ https://www.ncbi.nlm.nih.gov/pubmed/36425305 http://dx.doi.org/10.2147/DDDT.S398024 |